TBPH — Theravance Biopharma Share News
0.000.00%
Last trade - 00:00- $883.66m
- $528.80m
- $107.46m
Brief: Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares
Theravance Biopharma up on $250 mln capital return program
Brief: Theravance Biopharma Initiates $250 Mln Capital Return Program
Brief: Theravance Biopharma Inc QTRLY Loss Per Share $0.11
Theravance Biopharma Inc expected to post earnings of 11 cents a share - Earnings Preview
Brief: Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023
Brief: Theravance Biopharma To Sell Trelegy Ellipta Royalty Interests To Royalty Pharma For About $1.1 Bln In Upfront Cash With Over $1.5 Bln In Potential Total Value
Theravance Biopharma Inc reports results for the quarter ended in March - Earnings Summary
Brief: Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results
Theravance Biopharma Inc expected to post a loss of 11 cents a share - Earnings Preview
Theravance Biopharma Inc expected to post a loss of 11 cents a share - Earnings Preview
Theravance Biopharma hypotension drug fails to meet primary goal (updated)
Theravance Biopharma says hypotension drug failed to meet primary goal
Brief: Theravance Biopharma Inc Announces Results From Study 0170, A Second Phase 3 Study Of Ampreloxetine, In Patients With Symptomatic Neurogenic Orthostatic Hypotension (nOH)
Theravance Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Brief: Theravance Biopharma Reports Q4 And Full Year 2021 Results
Theravance Biopharma Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Theravance Biopharma, Inc. Announces Enrollment Of First Patient In Yupelri® Phase 4 Study
U.S. STOCKS ON THE MOVE-Zoom, Walt Disney, Best Buy